Fennec Pharmaceuticals Inc. (FENC) Stock Price & Analysis
Fennec Pharmaceuticals Inc. (FENC) is trading at USD 13.36, down 1.62% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
FENC last closed at USD 13.36; today's session has ranged USD 13.04–13.85 on volume of 517,266 shares. Market capitalization is —, with a 52-week range of USD 5.65–13.85 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FENC.md
Key facts (FENC)
- Last four reported quarters (through Sep 30, 2026): revenue $66.4M, net income $2.0M (3.1% margin) (SEC filings).
- Total return with dividends: 1Y +52.7% vs S&P 500 +11.9%; 5Y +36.0% vs S&P 500 +66.7%.
- Latest earnings report: 2026-11-12 (next date not yet announced).
- Dividend: FENC paid no cash dividend in the last five years.
- Short interest: 1.49% of float (as of 2026-10-30), 3.6 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FENC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $21.3M | $47.5M | $44.6M | $66.4M |
| Gross profit | — | $1.4M | $20.0M | — | — | — |
| Operating income | -$17.2M | -$22.6M | -$12.8M | $2.6M | -$6.3M | $3.7M |
| Net income | -$17.3M | -$23.7M | -$16.0M | -$436K | -$9.7M | $2.0M |
| EPS (diluted) | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 | — |
| Gross margin | — | 94.4% | 94.1% | — | — | — |
| Operating margin | — | -1471.6% | -60.1% | 5.4% | -14.1% | 5.6% |
| Net margin | — | -1544.9% | -75.5% | -0.9% | -21.8% | 3.1% |
| Revenue growth | — | — | +1284.5% | +123.7% | -6.1% | — |
| Cash + short-term investments | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M | — |
| Total debt | $5.0M | $24.9M | $30.9M | $19.3M | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (FENC)
Analysts (FENC)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| 2026-08-12 | B. Riley Securities | Target raised | Buy | $16 → $18 |
| 2026-08-12 | Wedbush | Target raised | Outperform | $13 → $16 |
Total return (dividends reinvested) (FENC)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | +52.7% | +36.0% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | +52.7% | +6.3% |
| Volatility (annualized) | 66.0% | 62.1% |
| Max drawdown | -35.8% (Feb 2026→Mar 2026) | -64.4% (Dec 2023→Nov 2024) |
Dividends (FENC)
FENC paid no cash dividend in the last five years.
Short interest (FENC)
454,453 shares sold short, 1.49% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 513,287 shares (-11.5%). Days to cover: 3.6 (short shares ÷ average daily volume).
FENC earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Mar 24, 2026 | Quarter ended Dec 31, 2025 | −$0.10 | $0.04 | Miss −$0.14 | -17.2% |
| Mar 10, 2025 | — | — | — | — | -7.0% |
| Mar 25, 2024 | — | — | — | — | +0.8% |
| Nov 7, 2023 | — | — | — | — | -4.3% |
| Aug 4, 2023 | — | — | — | — | +1.4% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
FENC recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | Schedule 13G/A | Solas Capital Management, LLC, FREDERICK TUCKER GOLDEN: 4.1% of shares, passive 5%+ holder (amended) |
| Nov 16, 2026 | Schedule 13G/A | Sonic Fund II, L.P., Sonic GP LLC: 4.5% of shares, passive 5%+ holder (amended) |
| Nov 12, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Oct 19, 2026 | Schedule 13G/A | Orin Hirschman, AIGH Capital Management LLC: 7.1% of shares, passive 5%+ holder (amended) |
| Sep 17, 2026 | 8-K | Other material event “On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 8.01, including Exhibit 99.1 attached hereto, shall not be…” |
| Aug 14, 2026 | Schedule 13G/A | Southpoint Master Fund, LP, Southpoint Capital Advisors LP: 0.0% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | Solas Capital Management, LLC, FREDERICK TUCKER GOLDEN: 5.4% of shares, passive 5%+ holder (amended) |
| Aug 13, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 13, 2026 | Schedule 13G/A | Rosalind Advisors, Inc., SALAMON STEVEN A J: 9.6% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
FENC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Norgine Pharma UK | “In March 2024, we announced that we entered into an agreement with Norgine, a leading European specialist pharmaceutical company.” |
Quoted from the company's 10-K filed Mar 27, 2026.
FENC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $0.18 | $0.14 | +28.5% | $22.1M | 4 |
| Next quarter (ends Mar 2027) | $0.13 | $0.11 | +18.2% | $22.5M | 3 |
| Current fiscal year (ends Dec 2026) | $0.41 | $0.33 | +21.3% | $74.7M | 4 |
| Next fiscal year (ends Dec 2027) | $1.02 | $0.95 | +7.6% | $106.7M | 5 |
FENC options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 348.7% | ±25.4% |
| Feb 19, 2027 | 93 | 99.1% | ±42.6% |
30-day implied volatility 128.7% vs 69% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 13.36 |
|---|---|
| Change | ▼ 1.62% (down) |
| Previous Close | USD 13.36 |
| Open | USD 13.36 |
| Day Range | USD 13.04 – 13.85 |
| 52-Week Range | USD 5.65 – 13.85 |
| Volume | 517,266 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (FENC)
Nexqual's technical model rates FENC "BUY" based on 5 bullish and 3 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.95 (overbought) |
| vs SMA50 | Above (USD 10.71) |
| MACD | 0.56 (positive) |
Earnings (FENC)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD 0.19 |
| Revenue Estimate | $22.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 0.12 vs est 0.11 ▲ beat |
| 2026-06-30 | USD 0.05 vs est 0.02 ▲ beat |
| 2026-03-31 | USD 0.01 vs est -0.02 ▲ beat |
| 2025-12-31 | USD -0.1 vs est 0.04 ▼ miss |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (FENC)
| Total Revenue | $66.37M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +57.30% |
| Gross Margin | +94.13% |
| Operating Margin | +5.60% |
| Profit Margin | +3.05% |
| ROE | +9.07% |
| Current Ratio | 6.11 |
| Total Cash | $48.68M |
| Total Debt | $0 |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (FENC)
Nexqual rates Fennec Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Strong — Revenue +71% (last 4 quarters to Sep 2026 vs the 4 before, SEC) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $49M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M (FY ended Dec 2025, 10-K) |
| Efficiency | Weak — ROE 4%, ROA 2.4% (last 4 quarters, SEC) |
Ownership (FENC)
| Insider Ownership | +13.93% |
|---|---|
| Institutional Ownership | +54.97% |
| Shares Outstanding | 35.31M |
| Float | 20.08M |
| Short % of Float | +1.49% |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
From Fennec Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, the FDA may require post-approval testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product's safety and effectiveness after commercialization.
Partnerships
- In March 2024, we announced that we entered into an agreement with Norgine, a leading European specialist pharmaceutical company.
- As previously noted, in March 2024, we entered into an agreement with Norgine, a leading European specialist pharmaceutical company.
Legal & Regulatory Risks (Item 1A, quoted)
- Risks Related to Third Parties
- We rely on third-party suppliers and other third parties for production of our product and our dependence on these third parties may impair the advancement of our research and development programs and the development of our product.
- We plan to rely on third parties to conduct clinical trials for our product. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain marketing approval for or commercialize our product outside of the United States.
- We or the third parties we rely on may encounter problems in clinical trials that may cause us or the foreign regulatory agencies to delay, suspend or terminate our clinical trials at any phase.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.19% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
| IMVT | Immunovant, Inc. | USD 33.3 | ▲ 0.27% |
| CGON | CG Oncology, Inc. | USD 79.9 | ▲ 1.22% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt